EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Platelet‐rich fibrin matrix as treatment for complex anal fistulae: A 3‐year experience at a tertiary centre

Alejandro Lusilla Lopez iD, Ursula Aho Fält iD, Pamela Buchwald iD, Louis Banka Johnson, Olof Grip iD

Colorectal Disease · 2026

DOI: 10.1111/codi.70447 ↗

At a glance

Journal article in Colorectal Disease, 2026. Written by Alejandro Lusilla Lopez and 4 co-authors. Institution: Department of Surgery, Skåne University Hospital, Malmö, Sweden. Major MEDLINE topics: Rectal Fistula, Platelet-Rich Fibrin. Cited 1 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: Region Skåne.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Aim

Treatment of complex anal fistulae remains a significant challenge for physicians and patients. A sphincter‐preserving technique with bioactive platelet‐rich fibrin matrix is one option. This three‐year study aimed to evaluate the efficacy of bioactive platelet‐rich fibrin matrix in treating complex anal fistulae.

Method

This retrospective study analysed data from 2019 to 2022 of patients diagnosed with complex anal fistulae treated with a platelet‐rich fibrin matrix at a tertiary centre. Endoanal ultrasound was used to morphologically characterize fistulas using Park's classification. Pearson's chi‐squared and Kaplan–Meier (log‐rank) analyses were used to evaluate between‐group differences.

Results

A total of 213 patients were included in the study (181 with cryptoglandular fistulae and 32 with Crohn's disease‐associated fistulae) with a median follow‐up of 6.6 months (range 0.5–67.1 months). Cavities and secondary tracts were identified in 14.6% and 34.7% of the patients, respectively. External opening closure occurred in 32% after one procedure and 43% cumulatively after a second intervention. Healing rates did not differ statistically by aetiology or fistula location. Cavities and secondary tracts were associated with failure. During follow‐up, 23% of the secondary tracts healed, whereas cavities derived no significant benefit from the intervention. No serious complications were reported.

Conclusion

Platelet‐rich fibrin matrix is a simple and safe sphincter‐preserving technique that achieves reasonably good results in the treatment of cryptoglandular and Crohn's disease‐associated fistulae. While secondary tracts may respond well, further research is required to optimize the management of fistulae associated with cavities.

Subjects

MeSH terms (MEDLINE)

Rectal FistulaPlatelet-Rich FibrinHumansRetrospective StudiesFemaleMaleTreatment OutcomeTertiary Care CentersAdultMiddle AgedCrohn DiseaseEndosonographyAged

Author keywords

Crohn's diseasecomplex anal fistularegenerative fistula treatment

Authors and institutions

  • Department of Surgery, Skåne University Hospital, Malmö, Sweden.
  • Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden.
  • Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden.

ORCID profiles: Alejandro Lusilla Lopez, Ursula Aho Fält, Pamela Buchwald, Olof Grip

Funding

  • Region Skåne

Cite

APA

Lusilla Lopez, A., Fält, U. A., Buchwald, P., Johnson, L. B., & Grip, O. (2026). Platelet‐rich fibrin matrix as treatment for complex anal fistulae: A 3‐year experience at a tertiary centre. Colorectal Disease. https://doi.org/10.1111/codi.70447

Vancouver

Lusilla Lopez A, Fält UA, Buchwald P, Johnson LB, Grip O. Platelet‐rich fibrin matrix as treatment for complex anal fistulae: A 3‐year experience at a tertiary centre. Colorectal Disease. 2026. doi:10.1111/codi.70447

BibTeX
@article{LusillaLopez2026,
  author = {Lusilla Lopez, Alejandro and Fält, Ursula Aho and Buchwald, Pamela and Johnson, Louis Banka and Grip, Olof},
  title = {Platelet‐rich fibrin matrix as treatment for complex anal fistulae: A 3‐year experience at a tertiary centre},
  journal = {Colorectal Disease},
  year = {2026},
  doi = {10.1111/codi.70447}
}
Start for free →